We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04428515
Recruitment Status : Recruiting
First Posted : June 11, 2020
Last Update Posted : September 29, 2022
Information provided by (Responsible Party):
Dr. Gregory Czarnota, Sunnybrook Health Sciences Centre

Brief Summary:
In this study, PA imaging will be used to examine the physiological and physical changes in lymph node involvements of head and neck cancer during radiotherapy with or without chemotherapy. Our objective in this pilot study will be to evaluate if PA parameters change within the lymph node involvements during chemoradiation therapy over time. Our hope is to use this information to correlate the changes in measured PA parameters with radiological response.

Condition or disease
Head and Neck Cancer

Detailed Description:

A trained clinical research coordinator will evaluate and authorize that each screened volunteer is a suitable subject for the study prior to enrolment. Written informed consent will be obtained from each participant prior to any clinical research scans to be performed on the subject. Those subjects who qualify will have their lymph node imaged using a PA imaging system. Up to 50 subjects will be recruited for this study.

Participants will be imaged 5 times over the course of radiotherapy regimen, which span up to 7 weeks. The patients will be assessed with MRI 10 to 12 weeks after the completion of Chemoradiation therapy as per the institution's standard of care. The lymph nodes will be measured by a staff radiologist, and the sizing information will be used to categorize patients into responders or non-responders. This information will be accessed using the patient's electronic medical record. Each patient will be assigned an anonymized accession number to the study that withholds any identifiers. There will be a complete accounting of all missing and excluded data, if any.

Although we do not anticipate any adverse events, all AEs will be documented in the CRF, and will be immediately reported to the REB, the overseeing physician responsible for the patient's care, and the study principal investigators.

Descriptive statistics (arithmetic mean, standard deviation, and coefficient of variation) and tabulation (stem and leaf plots) of study endpoints (absolute values and absolute value/comparator differences) will be used. PA datasets will be tested for normality, using a Shapiro-Wilk test (alpha=0.05). Comparative tests will use an independent t-test (or Mann Whitney test for normality violations) to compare the PA measurements between different breast masses (fibroadenomas, cysts, tumors).

In determining chemoradiation therapy evaluation, the primary endpoint, multiple linear regression models to relate study endpoints to subject characteristics and a logistic regression model will be used to build for multiparametric analysis of multiple PA parameters as a predictive model to pathological response. Descriptive statistics (frequency per scan, frequency per subject) and tabulation will be used to analyze the frequency of system malfunction.

Overall Survival Evaluation, the secondary endpoint, will use linear discriminant analysis to test for sensitivity, specificity and accuracy of the PA parameters as a diagnostic test. Receiver-operating characteristic will be used to test for PA cutoff values and a logistic regression model will be used to build for multiparametric analysis of multiple PA parameters as a predictive model to pathological response.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pilot Study to Evaluate Photoacoustic Imaging in Head and Neck Cancer
Actual Study Start Date : April 23, 2019
Estimated Primary Completion Date : April 23, 2024
Estimated Study Completion Date : April 23, 2024

Resource links provided by the National Library of Medicine

Radiotherapy Response Monitoring
Those undergoing radiation therapy treatment to their lymph nodes upon diagnosis of head and neck cancer

Primary Outcome Measures :
  1. Correlation of response to treatment between photoacoustic parameters and final radiological outcome. measures of outcome. [ Time Frame: 3 months ]
    The primary study endpoint will investigate changes of measured PA markers and compare these to radiological assessment of response of lymph node involvement to chemoradiation therapy for head and neck cancer. Changes in PA parameters will be made to a pre-treatment point over the course of treatment.

Secondary Outcome Measures :
  1. Correlation between photoacoustic parameters and five-year overall survival. [ Time Frame: 5 years ]
    The secondary study endpoint will correlate changes of measured PA markers to five-year overall survival (OS) of the same patient cohort. The survival status and of the patient cohort will be tracked after the treatment for five years based on the patient information system and follow up surveys if necessary.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Men or women with confirmed head and neck carcinoma and will be treated with radiotherapy.

Inclusion Criteria:

  • Histologically or cytologically confirmed head and neck carcinoma which has not been treated with any first-line therapy and will be treated with radiotherapy
  • Measurable disease by ultrasound, or MRI performed within 28 days prior to treatment
  • Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 or 1
  • Life expectancy of at least 6 months
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing:

    1. hemoglobin >90 mg/dL
    2. leukocytes >3,000/mL
    3. absolute neutrophil count >1,500/mL
    4. platelets >100,000/mL
    5. total bilirubin within normal institutional limits
    6. AST(SGOT)/ALT(SGPT) <2.5 X institutional upper limit of normal
    7. creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional upper limit of normal
  • Subjects must give appropriate written informed consent prior to participation in the study;
  • Subjects must be able and willing to comply with the safety procedures during the Scanning Period;

Exclusion Criteria:

  • Chemotherapy, radiotherapy, or major surgery within 4 weeks prior to registering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to registration
  • Receiving any other investigational agents
  • Known brain metastases
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition
  • Contraindications to radiotherapy such as but not limited to:

    1. previous radiotherapy to an involved area
    2. active collagen vascular disease
    3. genetic diseases associated with hyper-radiosensitivity
  • Any clinically serious infections requiring systemic anti-bacterial, antifungal or antiviral therapy
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection,
  • Symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia
  • History of active ongoing seizure disorder
  • Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04428515

Layout table for location information
Canada, Ontario
Sunnybrook Health Sciences Centre Recruiting
Toronto, Ontario, Canada, M4N3M5
Contact: Gregory J Czarnota, PhD, MD    (416)480-6128    gregory.czarnota@sunnybrook.ca   
Sponsors and Collaborators
Sunnybrook Health Sciences Centre
Layout table for investigator information
Principal Investigator: Gregory J Czarnota, PhD, MD Sunnybrook Health Sciences Centre
Layout table for additonal information
Responsible Party: Dr. Gregory Czarnota, Senior Scientist, Sunnybrook Health Sciences Centre
ClinicalTrials.gov Identifier: NCT04428515    
Other Study ID Numbers: 135-2018
First Posted: June 11, 2020    Key Record Dates
Last Update Posted: September 29, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Dr. Gregory Czarnota, Sunnybrook Health Sciences Centre:
Head and Neck
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site